NAYA Biosciences, Inc (NAYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NAYA Biosciences, Inc (NAYA) has a cash flow conversion efficiency ratio of -0.048x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-617.38K) by net assets ($12.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NAYA Biosciences, Inc (NAYA) total market value for the company's overall valuation and market capitalisation.
NAYA Biosciences, Inc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how NAYA Biosciences, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NAYA Biosciences, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NAYA Biosciences, Inc ranked by their cash flow conversion efficiency. See NAYA Biosciences, Inc (NAYA) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Adiuvo Investment SA
WAR:ADV
|
-0.005x |
|
Chanson International Holding Class A Ordinary Shares
NASDAQ:CHSN
|
0.073x |
|
GoldOn Resources Ltd
V:GLD
|
-0.098x |
|
Purple Biotech
NASDAQ:PPBT
|
-0.205x |
|
China Pharma Holdings Inc
NYSE MKT:CPHI
|
-0.028x |
|
PolyPlank publ AB
ST:POLY
|
0.323x |
|
Ostrom Climate Solutions Inc
V:COO
|
-0.097x |
|
Scout Security Ltd
AU:SCT
|
-0.203x |
Annual Cash Flow Conversion Efficiency for NAYA Biosciences, Inc (2007–2024)
The table below shows the annual cash flow conversion efficiency of NAYA Biosciences, Inc from 2007 to 2024. View NAYA Biosciences, Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.75 Million | $-2.97 Million | -0.233x | +95.62% |
| 2023-12-31 | $892.60K | $-4.76 Million | -5.327x | -178.87% |
| 2022-12-31 | $-977.61K | $-6.60 Million | 6.755x | +918.92% |
| 2021-12-31 | $7.31 Million | $-6.03 Million | -0.825x | +0.80% |
| 2020-12-31 | $5.74 Million | $-4.78 Million | -0.831x | -125.29% |
| 2019-12-31 | $-3.71 Million | $1.37 Million | -0.369x | -253.97% |
| 2018-12-31 | $-2.72 Million | $-652.97K | 0.240x | +560.10% |
| 2017-12-31 | $-4.99 Million | $-181.27K | 0.036x | -48.23% |
| 2016-12-31 | $-4.62 Million | $-323.90K | 0.070x | +73.81% |
| 2015-12-31 | $-3.76 Million | $-151.62K | 0.040x | -68.30% |
| 2010-12-31 | $-2.48 Million | $-315.99K | 0.127x | -57.65% |
| 2009-12-31 | $-3.08 Million | $-926.66K | 0.301x | -93.61% |
| 2008-12-31 | $-226.57K | $-1.07 Million | 4.708x | +309.46% |
| 2007-12-31 | $-100.93K | $-116.04K | 1.150x | -- |
About NAYA Biosciences, Inc
INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as soli… Read more